Abstract | BACKGROUND: METHODS: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg intravenously every week as a single agent. Patients who had a tumor response after 6 cycles were eligible to continue drug for a total of 12 cycles or 2 cycles after complete remission and then were observed without maintenance. RESULTS: Of 29 enrolled patients, 28 were evaluable for toxicity, and 27 were evaluable for efficacy. The median age was 69 years (range, 51-85 years), 86% of patients had stage IV disease, and 71% had > or = 2 extranodal sites. Patients had received a median of 4 prior therapies (range, 1-9 prior therapies), and 50% were refractory to the last treatment. The overall confirmed response rate was 41% (11 of 27 patients; 90% confidence interval [ CI], 22%-61%) with 1 complete response (3.7%) and 10 partial responses (37%). The median time to progression in all eligible patients was 6 months (95% CI, 3-11 months), and the median duration of response for the 11 responders was 6 months (range, 1-26 months). Hematologic toxicities were the most common, with 50% (14 of 28 patients) grade 3 and 4% (1 of 28 patients) grade 4 toxicities observed. Thrombocytopenia was the most frequent cause of dose reduction. CONCLUSIONS: Single-agent temsirolimus at a dose of 25 mg weekly is an effective new agent for the treatment of MCL. The 25-mg dose level retained the antitumor activity of the 250-mg dose with less myelosuppression. Further studies of temsirolimus in combination with other active drugs for MCL and other lymphoid malignancies are warranted.
|
Authors | Stephen M Ansell, David J Inwards, Kendrith M Rowland Jr, Patrick J Flynn, Roscoe F Morton, Dennis F Moore Jr, Scott H Kaufmann, Irene Ghobrial, Paul J Kurtin, Matthew Maurer, Christine Allmer, Thomas E Witzig |
Journal | Cancer
(Cancer)
Vol. 113
Issue 3
Pg. 508-14
(Aug 01 2008)
ISSN: 0008-543X [Print] United States |
PMID | 18543327
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Copyright | (c) 2008 American Cancer Society |
Chemical References |
- Antineoplastic Agents
- temsirolimus
- Sirolimus
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Administration Routes
- Drug Administration Schedule
- Female
- Humans
- Lymphoma, Mantle-Cell
(drug therapy, mortality)
- Male
- Middle Aged
- Recurrence
- Sirolimus
(administration & dosage, adverse effects, analogs & derivatives)
- Survival Analysis
- Treatment Outcome
- United States
|